ReviewFrontiers in oncology2014
Emerging understanding of multiscale tumor heterogeneity.
Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 118 citations in OpenAlex.
- Spatial omics illuminates tumor heterogeneity.Cell reports methods · 2026Review
- Mid-infrared microscopy for label-free digital staining: initial clinical assessment.Frontiers in bioengineering and biotechnology · 2026Article
- A review of exercise-induced epigenetic modifications in prostate tissue: implications for gene expression and tumor progression in prostate cancer.Cancer cell international · 2025Review
- Sensitizing solid tumors to CAR-mediated cytotoxicity by lipid nanoparticle delivery of synthetic antigens.Nature cancer · 2025Article
- Cancer stem cells in meningiomas: novel insights and therapeutic implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations.The Journal of biological chemistry · 2024Review
- Association between QT prolongation and cardiovascular mortality in cancer patients.Cardio-oncology (London, England) · 2024Article
- Spontaneous Fusion with Transformed Mesenchymal Stromal Cells Results in Complete Heterogeneity in Prostate Cancer Cells.Cancers · 2024Article
- Modelling the complex nature of the tumor microenvironment: 3D tumor spheroids as an evolving tool.Journal of biomedical science · 2024Review
- Engineering Heterogeneous Tumor Models for Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Real-time imaging of nanobubble ultrasound contrast agent flow, extravasation, and diffusion through an extracellular matrix using a microfluidic model.Lab on a chip · 2023Article
- Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes.Cancers · 2022Article
- Melanoma Detection by AFM Indentation of Histological Specimens.Diagnostics (Basel, Switzerland) · 2022Article
- Nanotechnology and Matrix Metalloproteinases in Cancer Diagnosis and Treatment.Frontiers in molecular biosciences · 2022Review
- Asymmetric Cell Division and Tumor Heterogeneity.Frontiers in cell and developmental biology · 2022Review
- Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology.Cancers · 2021Review
- Article
- Pre-existing Cell States Control Heterogeneity of Both EGFR and CXCR4 Signaling.Cellular and molecular bioengineering · 2021Article
- Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges.Frontiers in oncology · 2021Review
- Tumor heterogeneity in muscle-invasive bladder cancer.Translational andrology and urology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a multifaceted disease characterized by heterogeneous genetic alterations and cellular metabolism, at the organ, tissue, and cellular level. Key features of cancer heterogeneity are summarized by 10 acquired capabilities, which govern malignant transformation and progression of invasive tumors. The relative contribution of these hallmark features to the disease process varies between cancers. At the DNA and cellular level, germ-line and somatic gene mutations are found across all cancer types, causing abnormal protein production, cell behavior, and growth. The tumor microenvironment and its individual components (immune cells, fibroblasts, collagen, and blood vessels) can also facilitate or restrict tumor growth and metastasis. Oncology research is currently in the midst of a tremendous surge of comprehension of these disease mechanisms. This will lead not only to novel drug targets but also to new challenges in drug discovery. Integrated, multi-omic, multiplexed technologies are essential tools in the quest to understand all of the various cellular changes involved in tumorigenesis. This review examines features of cancer heterogeneity and discusses how multiplexed technologies can facilitate a more comprehensive understanding of these features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.